Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (10679)	11/12/1998 10:43:00 PM
From: Bradpalm1	Read Replies (2) \| Respond to of 119973

Rumors of the apparent efficacy of AGPH's anti-angiogenesis drug has implications beyond this single agent. It implies that anti-angiogenesis may work as a mechanism for treatment of many kinds of metastatic tumors and that Folkman is right but a little late in the game. AGPH's drug is being tested in Phase III trials as we speak and may get FDA approval as early as next year if all goes well. Folkman may get his Nobel but AGPH may win this race. ENMD should not be a long-term hold at this time (IMO) and the CEO may provide a nice exit point for tomorrow's trading. Bradpalm1